Zai Lab
At Zai, Mr. Smiley oversees all aspects of commercial, manufacturing, business development, finance, human resources, information technology, corporate affairs, and strategy.
Prior to joining Zai Lab, Mr. Smiley served as Chief Financial Officer for Eli Lilly and Company. He spent more than 25 years at Lilly, in a variety of positions of increasing responsibility. He served as senior vice president of finance, corporate controller, and treasurer, before being promoted to CFO. His experience at Lilly also included leading U.S. sales and marketing efforts focused on payers and public sector customers, business development, and mergers and acquisitions.
Before Lilly, Mr. Smiley worked in investment banking and consulting. He earned his bachelor’s degree in history from Harvard University.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.